Jörg Neermann, Ph.D., joined Immunic’s board in 2016. He acts as CEO of the privately held German biotech company Curexsys. Prior to this, he worked for more than fourteen years as a Partner at the life science-focused investment firm LSP and has served on numerous life sciences company boards (both private and public). In addition to the Immunic board, he currently is a member of the board of Vivoryon Therapeutics N.V..
Prior to joining LSP, Dr. Neermann was Managing Director at DVC Deutsche Venture Capital (a venture capital subsidiary of Deutsche Bank), where he built and ran its healthcare investment franchise. Prior to DVC, he started his venture capital career with Atlas Venture as an associate and investment manager.
During his career, he led and completed more than 80 financing transactions and was intimately involved in more than 15 M&A transactions and IPOs with a total transaction volume exceeding a billion euros.
Dr. Neermann studied biotechnology at the Technical University in Braunschweig, Germany, and the Massachusetts Institute of Technology in Cambridge, Mass., and holds a master’s degree and a Ph.D. in Biotechnology from the Technical University in Braunschweig, Germany. He also studied economics at the Technical University in Braunschweig, Germany, and at Harvard Business School.
Dr. Neermann brings to Immunic a strong scientific background and hands-on finance and investment expertise. He serves on the Audit Committee and the Compensation Committee of Immunic’s board.